Navigation Links
UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic
Date:6/9/2008

NEW YORK, June 9 /PRNewswire-USNewswire/ -- Officials with the U.S. Fund for UNICEF and global pharmaceutical company, Merck & Co., Inc. announced the donation and delivery of 100,000 doses of M-M-R(R) II (measles, mumps and rubella virus vaccine, live, attenuated) to the government of the former Soviet republic of Moldova, in response to an ongoing serious mumps outbreak in that country.

The vaccine is a combination vaccine against three diseases, measles, mumps, and rubella, and will be used to respond to the current mumps epidemic in a national immunization campaign for children and young people born between 1989 and 1994 to be carried out by the Moldovan Ministry of Health. The vaccine has been in use since the 1970s and more than 500 million doses of the vaccine have been distributed worldwide.

"Merck's donation of vaccines to assist in Moldova's immunization campaign is a shining example of corporate goodwill," said Caryl Stern, president and CEO, U.S. Fund for UNICEF. "We are pleased to partner with our friends at Merck to do whatever it takes to save a child."

"Public health crises such as this help remind us of the critical need for vaccinations. Merck's long history of success in discovering, developing and making potentially life saving vaccines helps us build a more productive and healthier future for all people," said Jeffrey Sturchio Ph.D., vice president of Corporate Responsibility for Merck. "UNICEF's first-hand knowledge of the situation and expertise in logistics made them the best choice to help coordinate the timely delivery of this important vaccine."

According to Moldovan Ministry of Health data, since the beginning of the year nearly 24,800 people have been infected with mumps, of which 9,615 persons were hospitalized, most of them having suffered complications such as pancreatitis, meningitis and orchitis. Children and young people between 14 and 24 years proved to be the most vulnerable, 80 percent of them
'/>"/>

SOURCE U.S. Fund for UNICEF
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. UNICEF Readies to Assist Mexican Flood Victims
2. George Harrison Fund for UNICEF Announces Donation for Bangladesh Cyclone Relief
3. Budding Young Artists Invited to Compete in 17th Annual Pier 1 Imports/UNICEF Greeting Card Contest
4. Actress/Producer Salma Hayek Launches The Pampers(R) One Pack = One Vaccine Program to Benefit UNICEF
5. UNICEF Launches Initiative to Provide Assistance to Children With Disabilities in Vietnam
6. im Initiative Participants Select UNICEF as Top Charity in First Year of Microsofts Initiative
7. U.S. Fund for UNICEF Honors Volunteers With PRESIDENTS VOLUNTEER SERVICE AWARD
8. Myanmar Cyclone: Women and Children Make up More than Half of Victims - UNICEF
9. Myanmar Cyclone a Childrens Catastrophe - UNICEF
10. UNICEF: Every Second Can Make a Difference to Myanmars Children; 20% Already Suffering from Diarrhea, Malaria reported
11. UNICEF REPORT: Desperate Conditions for Children in Camps Without Clean Water as Cyclone Aftermath Worsens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)..., COLLEGE PARK, MD. - A long history of terrori...s in Mumbai. The Global Terrorism Database (GTD), ...tional Consortium for the Study of Terrorism and R...00 terrorist attacks in India since 1970. Fataliti...eely available online. , The GTD is the most com...
(Date:12/2/2008)...ASHINGTON, Dec. 2 EIN N...te providing in-depth news on lung cancer. , ,...atients are finding out that information is one of..., Responding to the growing demand for accurate ...creening procedures and drugs to treat it, EIN New...
(Date:12/2/2008)..., , ROCKVILLE, Md., Dec. 2 /PRNewswire-USNe...ed sleep periods and increased supervision of work...ining environment, according to a new Institute of...are Research and Quality. , , The report i...ee that reviewed the relationship between resident...
(Date:12/2/2008)...OCHESTER, N.Y., Dec. 2 V...provider of quantitative imaging for clinical,tri...ceeds $27 million,compared to $14.7 million at th...se. The company calculates backlog as the amount r... contracts. The duration of the studies,included ...
Breaking Medicine News(10 mins):Health News:India terrorism by the numbers 2Health News:EIN News Introduces 'Lung Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 4Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3
...mount Americans spent on arthritis medications mor...ast-rising number of people// with the disease, in...h month and the inflation-adjusted cost per prescr...by a UCSF researcher. Results from a six-year stu...
...ebate on abortion is polarizing the US. Striking a...Spitzer has said that he would introduce// a bill ...week a conservative-dominated Supreme Court upheld...Ban Act, signed by President Bush in 2003. The ban...
...esponsibility and resources for public health and ...al councils rather than with the NHS, argues an ex...f Durham University says that partnerships between...HS would then become a true meeting of the two sid...
...tists at the Lundberg Laboratory for Cancer Resear...cademy in Sweden have discovered a //new hereditar...red that women possessing a certain hereditary def...k , almost twenty times, of contracting breast can...
Other Medicine News:Health News:Treatment Cost for Arthritis on the Rise: Study 2Health News:New York Governor to Introduce Bill to Strengthen Abortion Rights 2Health News:Local Councils Should Be Responsible for Tackling Health Inequalities 2Health News:Gene Behind Breast Cancer Found 2
(Date:12/1/2008)... SINGAPORE, Dec. 1 S*BIO Pte Ltd ...ical trial of SB1518, a potent and orally-active J...alia for patients with chronic idiopathic myelofib... evaluate the safety and tolerability of SB1518 in... 50 patients. The Phase 1 part of the study will ...
(Date:12/1/2008)... Baby Girl with Hypophosphatasia Treated With ENB...re in Winnipeg , , MONTREAL, Dec. 1 /PRNews...ch company focused on developing novel therapeutic... the first infant patient in its clinical program ...ating Enzyme Replacement Therapy (ERT) with ENB-00...
(Date:12/1/2008)... , Abstinence is still the best policy , ...ire/ -- A new study from Mayo Clinic finds the use...ating alcoholic hepatitis, an acute inflammation o...ohol. The results of the study are published in th...w.gastrojournal.org/ ). , , VIDEO ALERT: A...
(Date:12/1/2008)... KVISTGARD, Denmark, December 1 /PRNewswire-F...ued in 2007 with the intent to procure an MVA-base...s and Government Services,Canada, on behalf of th...rded,a contract to Bavarian Nordic for the delive...es intend to use IMVAMUNE(R) as part of the,count...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 1BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 3Anesiva Announces May 22 2008 Presentation at Citi Investment Research Global HealthCare Conference 19576 1New Gene Methylation Test for Prostate Cancer Available 2096 1Jazz Pharmaceuticals to Present at Investor Conferences 19573 1
...(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, I...ed today that the,first results from testing of a ...T-VACC™, have been published in the journal,... Infection and,Immunity, v. 75, p. 3043 ). These r...immunity elicited by a multivalent vaccine,that is...
... Update to Timeline for Second Pivotal Phase 3 Tri...Call/ -- Advanced Life,Sciences Holdings, Inc. , t...ficacy data from Trial CL-06, the first of two,piv...e safety and,effectiveness of cethromycin, a novel...nity acquired pneumonia (CAP). The Company,also pr...
Other Medicine Technology:DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
Steroid-eluting, screw-in pacing lead
Tendril SDX is one of the world's thinnest, extendable/retractable pacing leads. Implantable with a 7 F introducer, the lead's reduced body diameter is designed to lower the incidence of venous obstr
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase.
Medicine Products: